In general, PD-L1+, strongly immunogenic patients had the highest clinical response rate for all three cancer types (excluding single-sample groups), and PD-L1-, weakly immunogenic patients had the lowest response rate (or in the case of melanoma, the second-lowest). This evidence concerns the gene CD274 and melanoma.